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In Brief
Berkers et al. demonstrate that stem cell
cultures (organoids) can be a tool for
personalized medicine. They show a high
correlation between in vitro and in vivo
effects of drugs and demonstrate good-
to-excellent predictive values of the
organoid test for preclinical identification
of responders to CFTR modulators.
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https://doi.org/10.1016/j.celrep.2019.01.068SUMMARY
In vitro drug tests using patient-derived stem cell
cultures offer opportunities to individually select
efficacious treatments. Here, we provide a study
that demonstrates that in vitro drug responses in
rectal organoids from individual patients with cystic
fibrosis (CF) correlate with changes in two in vivo
therapeutic endpoints. We measured individual
in vitro efficaciousness using a functional assay
in rectum-derived organoids based on forskolin-
induced swelling and studied the correlation with
in vivo effects. The in vitro organoid responses corre-
lated with both change in pulmonary response and
change in sweat chloride concentration. Receiver
operating characteristic curves indicated good-to-
excellent accuracy of the organoid-based test for
defining clinical responses. This study indicates
that an in vitro assay using stemcell cultures can pro-
spectively select efficacious treatments for patients
and suggests that biobanked stem cell resourcesCell Rep
This is an open access article under the CC BY-Ncan be used to tailor individual treatments in a
cost-effective and patient-friendly manner.INTRODUCTION
Functional drug testing on cells or tissue cultures of patients may
represent a major step forward for selecting efficacious treat-
ments in an individual setting. Our identification of Lgr5 as a
marker of crypt stem cells and the development of technology
to grow functional epithelial organoids from such stem cells
allows the generation of disease- and patient-specific living bio-
banks (Barker et al., 2007; Sato et al., 2009; van de Wetering
et al., 2015). These biobanks could serve as important resources
for drug development and scientific studies, but examples
demonstrating the validity of these tissue resources for the indi-
vidual prediction of clinical drug efficacy are currently lacking.
Cystic fibrosis (CF) is a genetic disease that is caused by mu-
tations of the gene encoding for the cystic fibrosis transmem-
brane conductance regulator (CFTR) protein, which leads to
impaired protein function (Riordan et al., 1989).
Over 2,000 CFTR mutations have been identified (http://www.
genet.sickkids.on.ca/) and are associated with a variety oforts 26, 1701–1708, February 12, 2019 ª 2019 The Author(s). 1701
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
clinical phenotypes (https://www.cftr2.org/) (Sosnay et al., 2013;
Cutting, 2015). Recently developed drugs for CF aim to restore
CFTR protein function. Lumacaftor (VX-809) and tezacaftor
(VX-661) are corrector drugs, influencing trafficking of the
CFTR protein to the apical membrane, while ivacaftor (VX-770)
is a potentiator drug, improving the function of the CFTR protein
that is present at the apical membrane. In previous work, we
showed that also the natural food components genistein
and curcumin have potentiator activity in vitro, albeit at
reduced efficacy and potency as compared to ivacaftor (Dekkers
et al., 2016b). Currently, three CFTR-modulating drugs are regis-
tered for the treatment of CF patients with specific CFTR muta-
tions: ivacaftor (VX770; Kalydeco) for patients with different
CFTR gating mutations and patients with an R117H mutation,
and a combination of ivacaftor and the CFTR correctors luma-
caftor or tezacaftor (respectively, VX770+VX809, Orkambi, and
VX770+VX661, Symdeco/Symkevi) for patients homozygous
for the F508del mutation and some mutations associated with
residual function in the case of Symdeco/Symkevi treatment
(Ramsey et al., 2011; De Boeck et al., 2014; Moss et al., 2015;
Wainwright et al., 2015; Rowe et al., 2017; Taylor-Cousar et al.,
2017).
This CFTR genotype-based stratification for drug prescription
presents a challenge for the inclusion of many people with rare
CFTR mutations who are not included into clinical trials due to
low prevalence of the mutation and lack of mechanistic insights.
A recent label extension of ivacaftor by the US Food and Drug
Administration (FDA), based on in vitro data of heterologous
cell lines and mode of action, signals a paradigm shift of the reg-
ulatory pathway to faster drug access for people with rare CFTR
mutations (Ratner, 2017). In previous work, we showed that for-
skolin-induced swelling (FIS) of rectal organoids can be used to
quantify the function of the CFTR protein in response to CFTR-
modulating drugs. Forskolin raises intracellular cyclic AMP that
leads to opening of the CFTR ion channel and subsequent ion
and fluid transport into the organoid lumen in a CFTR-dependent
manner. This readout functionally assesses the impact of both
CFTR mutations and additional patient-specific genetic factors
that act on CFTR function (Dekkers et al., 2013). In previous
work, we showed that the in vitro response that was measured
in rectal organoids correlates with average clinical responses
described in patient populations with corresponding genotypes
(Dekkers et al., 2016a). We also predicted the lack of efficacy
of PTC124 (ataluren) in a recent phase 3 clinical trial, by testing
of PTC124 in rectal organoids from people carrying nonsense
mutations (Zomer-van Ommen et al., 2016; Zainal Abidin et al.,
2017). In vitro functional testing in rectal organoids of an individ-
ual patient may be a next step to facilitate rapid individual access
to treatment for patients with rare CFTR mutations.
Currently, it is not clear whether the in vitro FIS response to
CFTR-modulating drugs correlates with the in vivo response at
the level of the individual patient. Current clinical outcome pa-
rameters and in vivo or ex vivo biomarkers of CFTR function
are highly valuable for measurement of average treatment ef-
fects in clinical trials, but they do not correlate at the individual
level. A recent meta-study found a small correlation between
the in vivo pulmonary response and the response of an in vivo
biomarker of CFTR function (sweat chloride concentration1702 Cell Reports 26, 1701–1708, February 12, 2019[SCC]), but this study also indicated that individual responses
in SCC had a low predictive value for corresponding pulmonary
response. Our previous study with rectal organoids showed that
two individuals who carried mutations that were not yet charac-
terized, could be successfully selected for a treatment with iva-
caftor (Dekkers et al., 2016a). We also recently described that
FIS measurements of individual patients were related to clinical
indicators of CF disease severity, and comparison of FIS and
SCC suggested more precise quantification of CFTR function
by FIS (de Winter-de Groot et al., 2018). We here describe the
correlation between the response of FIS of rectal organoids
and the in vivo therapeutic response for individual CF patients
with multiple CFTR genotypes who were treated with several
CFTR-modulating drugs, and we study the predictive values of
the organoid FIS test for the clinical response.
RESULTS
To evaluate the relation between drug response in in vitro
cultured organoids and therapeutic effect in vivo, we studied
37 paired in vitro-in vivo responses to three CFTR-modulating
treatments in 24 subjects with CF (baseline characteristics are
provided in Table 1). Fifteen patients with the ivacaftor-respon-
sive S1251N mutation received ivacaftor (De Boeck et al.,
2014). Thirteen of these patients first received a combination of
the possible CFTR-potentiating food supplements genistein
and curcumin before receiving ivacaftor (Dekkers et al.,
2016b). The other nine patients carried at least one rare CFTR
mutation with unknown clinical response and were selected for
off-label treatment based on the organoid response to either iva-
caftor or ivacaftor plus lumacaftor. Apart from the CFTR geno-
type, there were no relevant differences in the baseline clinical
characteristics (such as percentage of predicted forced expira-
tory volume in 1 s [ppFEV1] or SCC values) between patients
that received one or two treatments.
We quantified CFTR modulator responses in vitro by assess-
ment of FIS of patient-derived rectal organoids that were previ-
ously cultured and stored in a biobank (Figures 1A and 1B
show an example; individual measurements for all patients are
provided in Figure S1). Organoid swelling was assessed after
adding various concentrations of forskolin to facilitate optimal
detection of drug response across the cohort for the various
drugs (Dekkers et al., 2013). We used two outcome parameters
to evaluate the in vivo clinical effect of a treatment: change in
ppFEV1 and change in SCC. Pearson’s correlations between
organoid response and pulmonary response were analyzed in
a subgroup of patients who had a ppFEV1 R40% and %90%
before the start of treatment, to limit non-response of this
endpoint (ceiling effects at >90% or irreversible lung damage
at <40%), as is usual in clinical trials (Ramsey et al., 2011; De
Boeck et al., 2014; Moss et al., 2015; Wainwright et al., 2015;
Wood et al., 2013; Taylor-Cousar et al., 2018). The organoid
FIS positively correlated with both the pulmonary response
(change in ppFEV1; n = 21, r = 0.610, p = 0.003; Figure 1C) and
the change in SCC (n = 18, r = 0.762, p % 0.001; Figure 1D).
As observed in other studies with CFTR modulators, the
two in vivo endpoints appeared only weakly correlated, in a
statistically non-significant manner (SCC versus ppFEV1,
Table 1. Patient Characteristics and Treatment Regimes
Treatment (Duration
in Weeks) CFTR-Genotype
Median Age in Years
at Baseline (IQR)
Median ppFEV1
at Baseline (IQR)
Median SCC in mmol/L
at Baseline (IQR)
Genistein plus
curcumin (8)
S1251N (p.Ser1251Asn)/F508del (p.Phe508del),
n = 12a
15.0 (10.0–33.0) 75.5 (64.0–93.8) 80.0 (65.5–91.0)
S1251N (p.Ser1251Asn)/R117H (p.Arg117His),
n = 1a
Ivacaftor (4–8) S1251N (p.Ser1251Asn)/F508del (p.Phe508del),
n = 12a
16.5 (11.3–35.8) 73.0 (59.5–94.5) 77.0 (64.0–94.0)
S1251N (p.Ser1251Asn)/R117H (p.Arg117His),
n = 1a
S1251N (p.Ser1251Asn)/A455E (p.Ala455Glu),
n = 1
S1251N (p.Ser1251Asn)/1717-1G>A (c.1585-
1G>A), n = 1
G1249R (p.Gly1249Arg)/F508del (p.Phe508del),
n = 2
G461R (p.Gly461Arg)/F508del (p.Phe508del), n = 2
S945L (p.Ser945Leu)/F508del (p.Phe508del), n = 1
R334W (p.Arg334Trp)/R764X (p.Arg764X), n = 1
R553X (p.Arg553X)/4375-3T>A (c.4243-3T>A),
n = 1
Lumacaftor plus
ivacaftor (4)
R347P (p.Arg347Pro)/F508del (p.Phe508del), n = 1 35.0 30.0 97.0
W1282X (p.Trp1282X)/F508del (p.Phe508del),
n = 1
CFTR, cystic fibrosis transmembrane conductance regulator; IQR, interquartile range; ppFEV1, percentage of predicted forced expiratory volume in
1 s; SCC, sweat chloride concentration.
aPatients were treated with both genistein/curcumin and ivacaftor.n = 18, r = 0.366, p = 0.14; Figure 1E). We observed no big
impact on the correlation of the repeated genistein plus curcu-
min and ivacaftor measurements; for ppFEV1, n = 21, r =
0.624, p % 0.001, and for SCC, n = 18, r = 0.716, p % 0.001
(Figure S2). In accordance with previous observations, all corre-
lations were optimal when organoid responses at 0.128 mM for-
skolin were used (Table S1) (Dekkers et al., 2016a). Patients with
a ppFEV1 >90% or ppFEV1 <40% before the start of the treat-
ment did not show a clear correlation between the organoid
response and change in ppFEV1, despite an identical correlation
between organoids and SCC (Figures 1F and 1G). The data of all
patients combined showed correlations of organoids with both
ppFEV1 (n = 35, r = 0.575, p % 0.001; Figure 1I) and SCC (n =
33, r = 0.708, p % 0.001; Figure 1J), but a statistically signifi-
cant relation between ppFEV1 and SCC was not observed (Fig-
ures 1H and 1K). People with rare mutations who were selected
by organoids prior to treatment showed a median increase of
10% in ppFEV1 (n = 7, p = 0.058) and a reduction of 39 mmol/L
in SCC (n = 6, p = 0.028). Collectively, these data demonstrate
that in vitro CFTR modulator responses in organoids correlate
with two important therapeutic endpoints.
Prediction of Clinical Responses Using Organoids
Next, we generated receiver operating characteristic (ROC)
curves to examine the predictive potential of different orga-
noid-based thresholds for identifying clinical responders. We
dichotomized both the ppFEV1 and SCC response into changesthat are generally considered clinically significant and beyond
the test variability (changes in ppFEV1 >5%, or SCC >20 mM
or a combined change in ppFEV1 >5% and SSC >20 mM) and
changes that are not (Seliger et al., 2013). The area under the
ROC curve provides a general measure for test accuracy and
was 0.837 (95% confidence interval [CI], 0.661–1.000) for pre-
dicting responders in ppFEV1 and increased toward 0.938
(95% CI, 0.830–1.000) for predicting responders in either SCC
or SCC and ppFEV1 (Figure 2A). When repeated measurements
were taken into account, the area under the ROC curve did not
change. A Youden index was used to select an organoid cutoff
point with the most optimal combination of sensitivity and spec-
ificity in an unbiased fashion (Youden, 1950). The selected cutoff
value to identify responders in both SCC and ppFEV1 had a
sensitivity of 0.80 and a specificity of 1.00 with a corresponding
Youden index of 0.8 for identifying responders and non-re-
sponders in both ppFEV1 and SCC. The associated positive
and negative predictive values were 100% and 80%, respec-
tively. Since data-driven selection of the Youden index might
cause over-estimation of both sensitivity and specificity, we
performed a leave-one-out cross-validation to further validate
our findings (Leeflang et al., 2008). This additional analysis
showed a sensitivity of 0.70 and specificity of 1.00, with a corre-
sponding Youden index of 0.70.
For patients that started with a ppFEV1 <40% or >90%, the
ROC curve had an area under the curve between 0.694 and
0.767 (Figure 2B). For the total group of patients that was treated,Cell Reports 26, 1701–1708, February 12, 2019 1703
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Figure 1. Significant Correlation between Individual In Vitro Organoid Response and In Vivo Change in ppFEV1 and SCC
(A) Confocal images of the forskolin-induced swelling (FIS) of organoids with an F508del/S1251Nmutation. Images are taken 0 and 60 min after adding DMSO,
genistein plus curcumin and ivacaftor (VX-770), in combination with forskolin.
(B) AUC of the swelling of organoids aftermeasuring for 60min. The graph shows responses after adding eight different concentrations of forskolin in combination
with either DMSO or a CFTR-modulating treatment. Mean ± SD.
(C and D) Pearson correlations between response of the organoids of an individual patient upon CFTR-modulating treatment in combination with 0.128 mM
forskolin and the in vivo response (change in ppFEV1, as shown in C, and change in SCC, as shown in D) of the same patient to the same treatment for patients
who had a ppFEV1R40% and%90% before the start of treatment.
(E) Pearson correlation between change in ppFEV1 and change in SCC of individual patients upon a CFTR-modulating treatment for patients who had a
ppFEV1R40% and%90% before the start of treatment.
(F and G) Pearson correlations between response of the organoids of an individual patient upon CFTR-modulating treatment in combination with 0.128 mM
forskolin and the in vivo response (change in ppFEV1, as shown in F, and change in SCC, as shown in G) of the same patient to the same treatment for patients
who had a ppFEV1 <40% or >90% before the start of treatment.
(H) Pearson correlation between change in ppFEV1 and change in SCC of individual patients upon a CFTR-modulating treatment for patients who had a
ppFEV1 <40% or >90% before the start of treatment.
(legend continued on next page)
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Figure 2. Predicting Individual Clinical Response by Using Rectal Organoids of a Patient
(A) Receiver operating characteristic (ROC) curves of predicting which patient shows a response in ppFEV1, SCC, and both ppFEV1 and SCC for patients who had
a ppFEV1R40% and%90% before the start of treatment.
(B) ROC curves of predicting which patient shows a response in ppFEV1, SCC, and both ppFEV1 and SCC for patients who had a ppFEV1 <40% or >90% before
the start of treatment.
(C) ROC curves of predicting which patient shows a response in ppFEV1, SCC, and both ppFEV1 and SCC for all patients that received treatment.the area under the ROC curve varied between 0.783 and 0.869
(Figure 2C). Because of the small sample size, we did not calcu-
late ROC curves for the group of patients that had at least one
rare CFTR mutation.
In conclusion, the organoid-based test displayed excellent
accuracy (area under the curve [AUC] of ROC curve, >0.9) for
identifying clinical responses defined by changes in SCC and
ppFEV1 or only SCC, while good accuracy (AUC of ROC curve,
between 0.8 and 0.9) was observed for identifying clinical re-
sponses defined only by ppFEV1 (Metz, 1978).
DISCUSSION
This study aimed to provide evidence that FIS of rectal orga-
noids can act as a prospective biomarker for in vivo CFTR
modulator responses. We demonstrated here that individual
in vitro CFTR modulator responses in these patient-derived
stem cell cultures correlate with two independent indicators
of therapeutic response in vivo. The moderate correlation be-
tween FIS and ppFEV1 and higher correlation between FIS
and SCC (an in vivo biomarker of CFTR function) is in agree-
ment with the higher impact of non-CFTR-dependent factors
on variation in pulmonary function as compared to SCC (Cut-
ting, 2015; Collaco et al., 2016). We did not find a statistically
significant correlation between change in SCC and ppFEV1,
probably because of a weaker correlation between these
outcome measurements in combination with a small sample
size, as was previously also observed in other studies with
comparable sample sizes (Accurso et al., 2010). These in vivo
endpoints are suitable to indicate treatment effects at a group
level, but non-CFTR-dependent variation in ppFEV1 and SCC
probably limits their precision and accuracy for informing on(I and J) Pearson correlations between response of the organoids of an individual p
and the in vivo response (change in ppFEV1, as shown in I, and change in SCC,
received treatment.
(K) Pearson correlation between change in ppFEV1 and change in SCC of indivi
treatment.
See also Figures S1 and S2 and Table S1.individual CFTR function modulation (Fidler et al., 2016). In
contrast, in vitro FIS is completely CFTR dependent and has
sufficient sensitivity to quantitate CFTR modulator activity,
and the repeated measurements increase precision. These
properties likely facilitate that FIS has sufficient accuracy to
inform on both ppFEV1 and SCC (or their combination), sug-
gesting that FIS is a potent biomarker to quantitate individual
CFTR modulator responses.
Our dataset provides a first analysis of the predictive potential
of the rectal organoids to identify clinical responders and non-re-
sponders to treatment. Our data support that FIS can be used to
prospectively select responders and non-responders to CFTR
modulator treatments but the cutoff value with the highest You-
den index still needs to be interpreted carefully as well as the
definition of clinical responders. The Youden index selects the
most optimal ratio between sensitivity and specificity, but a
different threshold with a higher negative predictive value may
be preferential to limit the exclusion of treatment responders
(e.g., an organoid threshold with a negative predictive value of
100% would have a positive predictive value of 77%). Addition-
ally, it remains unclear how short-term treatment responses indi-
vidually translate into long-term clinical response. It could there-
fore be that the definitions for long-term clinical responders are
different, leading to other threshold values of predictive tests.
We observed that the correlation of the organoid test with
response in ppFEV1 was modified by baseline ppFEV1, despite
similar correlation in SCC in both groups with differences in
baseline ppFEV1. This supports that biomarkers of CFTR func-
tion such as organoid-based measurements have an important
role for assessment of CFTR modulator responses in subjects
where clinical domain indicators are unsuited to measure thera-
peutic response.atient uponCFTR-modulating treatment in combination with 0.128 mM forskolin
as shown in J) of the same patient to the same treatment for all patients that
dual patients upon a CFTR-modulating treatment for all patients that received
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There are several limitations in this study. First, the open-label
setting of treatments can induce bias in the acquisition of clinical
data. Potentially, ppFEV1 might have been influenced, but this is
unlikely for SCCmeasurements. However, we do not expect that
the open-label setting has strongly affected the in vitro-in vivo
correlation, since the clinical observers and patients were
blinded for the in vitro drug responses and vice versa. Second,
the study is biased for potentiator treatments. The area under
the ROC curves may be different when patients are stratified
for different CFTR modulator treatments such as corrector/
potentiator combinations. Also, the cutoff values of ppFEV1
and SCC that were used to define a clinical responder may not
be fully accurate in identifying long-term clinical responders to
treatment, and changing these cutoff values will lead to different
ROC curves. Third, patient subgroups with differences in orga-
noid baseline CFTR functions may require different organoid
test conditions (e.g., different forskolin conditions) for better
predictive values. Fourth, it remains challenging to estimate
adequate drug concentrations in the organoid tests as to
optimally reflect the in vivo tissue concentration. For ivacaftor
and lumacaftor, we relied on average blood concentrations to
determine the in vitro drug concentrations (European Medicines
Agency, 2018a, 2018b). For genistein and curcumin, lack of in-
formation on in vivo tissue concentrations may have resulted in
overdosing the in vitro situation, which can lead to overestima-
tion of their potential in vivo effect. Most importantly, larger
follow-up studies remain needed to define more precisely how
organoid-based measurements, and possibly other short-term
endpoints, can predict long-term individual benefit to various
CFTR modulator treatments.
Apart from the performance of FIS as a biomarker of treatment
response in this study, the rectal organoids provide additional
benefits over other biomarkers of CFTR function. Rectal organo-
ids are adult stem cell cultures that can be generated from a
single rectal biopsy and cultured over 6 months while maintain-
ing patient-specific CFTR modulator response (Clevers, 2016;
Dekkers et al., 2016a). Rectal biopsies are accessible in most
subjects independent of age and can be shipped to dedicated
centers for organoid testing within weeks and stored in living bio-
banks, which enables future drug testing (Dekkers et al., 2016a).
The FIS readout appears also not affected by CF disease pheno-
type (e.g., irreversible damage and inflammation in pulmonary
markers). Currently, the immediate impact can be the selection
of people for treatments independent of the CFTR genotype,
both for CFTR modulators on the market and in development.
For people having access to treatment, wemay be able to further
individually tailor treatments to maximize clinical benefits (Beek-
man, 2016).
Conclusion
In vitro drug efficacy measurements by FIS in rectal organoids
of individuals with CF correlate with the most important in vivo
response indicators of CFTR modulators (change in ppFEV1
and SCC). The data further suggest that thresholds can be
established to prospectively identify clinical responders with
acceptable positive and negative predictive values. Organoid
testing can provide a patient-friendly and cost-effective
approach to increase access to treatment for patients with CF,1706 Cell Reports 26, 1701–1708, February 12, 2019and optimize risk-benefit and cost-effectiveness of treatments.
This study is a first example that in vitro tests using cultures of
patient stem cells, stored in living biobanks, can be used to pre-
dict individual treatment benefits.STAR+METHODS
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STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Biological Samples
Human rectal tissue This paper http://hub4organoids.eu/ N/A
Chemicals, Peptides, and Recombinant Proteins
B27 supplement with Vitamin A Thermo Fisher Scientific: Invitrogen Cat# 17504-044
N-Acetylcysteine Sigma Aldrich Cat# A9165-25 g
Nicotinamide Sigma Aldrich Cat# N0636
Mouse Epithelial Growth Factor Invitrogen Cat# PMG8043-1mg
TGFb type I Receptor inhibitor (A83-01) Tocris Cat# 2939
p38 MAPK inhibitor (SB202190) Sigma Aldrich Cat# S7067-25mg
Calcein, AM Life Technologies: GIBCO Cat# C3100MP
Forskolin Sigma Cat# F3919-10mg
Lumacaftor (VX-809) Selleckchem Cat# s1565
Ivacaftor (VX-770) Selleckchem Cat# s1144
Genistein Sigma Cat# 92136-10mg
Curcumin Sigma Cat# C7727-500mg
Deposited Data
CFTR2 database Johns Hopkins University / Hospital
for Sick Children / CF Foundation
https://www.cftr2.org/
Experimental Models: Cell Lines
Human rectal organoid lines This paper http://hub4organoids.eu/ N/A
L- Wnt 3A producing cell line http://hub4organoids.eu/ N/A
Hek293T – Noggin hFc cell line http://hub4organoids.eu/ N/A
Hek293T – R-spondin-1 mFc cell line Trevigen Cat# 3710-001-K
Software and Algorithms
Zen Image analysis software module Zeiss https://www.zeiss.com/microscopy/
int/products/microscope-software/zen/
image-analysis.html
SPSS IBM https://www.ibm.com/analytics/nl/nl/technology/
spss/
R-studio https://www.rstudio.com/
Graphpad prism Graphpad https://www.graphpad.com/scientific-
software/prism/
Other
Matrigel (protein concentration between 9.8-
10.2 mg/ml)
Corning Cat# 354230CONTACT FOR REAGENT AND RESOURCE SHARING
Further information and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Dr. Jeffrey
M. Beekman (j.beekman@umcutrecht.nl).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Forskolin induced swelling of rectal organoids
Rectal organoids were cultured according to previously described protocols, and are accessible for study by contacting the Hu-
brecht Organoid Technology foundation (http://hub4organoids.eu/) (Sato et al., 2011; Dekkers et al., 2016a). Forskolin-inducedCell Reports 26, 1701–1708.e1–e3, February 12, 2019 e1
swelling of rectal organoids is a fully CFTR-dependent readout and was measured to indicate baseline CFTR function and response
to drugs (Dekkers et al., 2013, 2016a). The organoid response to a drug was calculated by subtracting the DMSO response at the
same forskolin concentration.
Patient selection
A total of 24 patients (15males and 9 females, median age 16.0 years) were included in this study. From these 24 patients, 15 patients
had at least one S1251Nmutation and were treated with CFTRmodulators as part of a clinical trial aiming to compare different CFTR
potentiator treatments (NTR4585 and NTR4873). Thirteen of these 15 patients participated in both clinical trials and therefore
received two different CFTR modifying treatments. The remaining 9 patients carried at least one rare CFTR mutation and were
selected for off-label CFTR modulator treatments based on the organoid response and clinical necessity. A rare mutation was
defined as a mutation with a prevalence of less than 1.0% in the Dutch CF population of which no data on clinical drug responsive-
ness was available in literature at the time of biopsy (Dutch Cystic Fibrosis Foundation, 2016). More information on the clinical char-
acteristics of the selected patients is shown in Table 1. All patients (and/or their legal representatives) gave informed consent for
rectal biopsies, generating and testing of their individual organoids as well as for (data collection on the effect of) clinical treatment.
Clinical endpoints
In vivo therapeutic effect in the patients with an S1251Nmutation was measured by absolute change after 8 weeks of CFTR modu-
lator treatment in comparison with pretreatment baseline value. Data from people with rare mutations receiving either ivacaftor or
lumacoftor/ivacaftor was collected between 4-8 weeks after initiation of treatment. Forced expiratory volume in one second is a
widely used readout to assess pulmonary function, and was expressed as percent predicted for body height, age and gender
(ppFEV1). Sweat chloride concentration (SCC) measurements were assessed as this is currently the best established in vivo
biomarker of CFTR function.
METHOD DETAILS
Forskolin-induced swelling of rectal organoids
Organoid swelling was measured in duplicate at multiple independent culture time points as indicated in Figure S1, with 4-8 different
concentrations of forskolin as previously described (Dekkers et al., 2013, 2016a; Boj et al., 2017). The CFTR modulators (3 mM
VX-770/ivacaftor (Selleck Chemicals LLC) or a combination of 10 mM genistein (Sigma) plus 50 mM curcumin (Sigma)) were directly
added to the organoids with forskolin, except for VX-809/lumacaftor (3 mM, Selleck Chemicals LLC) that was pre-incubated for 24h.
Organoids were fluorescently labeled and total area per well and time point wasmonitored by a Zeiss LSM800 confocal microscope.
A Zen Image analysis software module (Zeiss) was used to quantify the organoid response (area under the curve measurements of
relative size increase of organoids after 60 minutes forskolin stimulation, t = 0 min baseline of 100%).
Evaluation of clinical treatment
For all treatments both the patients and those who were involved in clinical data collection were blinded for the magnitude of the
in vitro drug response of the patients’ organoids and vice versa. The ppFEV1 wasmeasured according to ATS-ERS standards (Amer-
ican Thoracic Society, 1995; Beydon et al., 2007). The SCC was measured using the Macroduct system and performed according
to the most recent version of the standard operating procedure of the European Cystic Fibrosis Society-Clinical Trial Network.
QUANTIFICATION AND STATISTICAL ANALYSIS
The primary outcome of the study was the correlation (Pearson) between the in vitro organoid and in vivo effects (change in ppFEV1
and SCC) plus the predictive capacity of the organoid model, in patients that had a baseline ppFEV1 between 40 and 90 percent.
When a change in ppFEV1 or SCC was missing, a patient was excluded from that part of the analysis. In a secondary analysis,
we calculated the correlation and predictive capacity for patients that had a baseline ppFEV1 of < 40 or > 90 percent as well as
for the total group of patients that was treated. Finally we used the wilcoxon signed rank test to examine the clinical response of pa-
tients with at least one rare CFTRmutation (non- F508del or S1251N) who had a response in their rectal organoids (AUC at 0.128 mM
forsklin > 1000) to the CFTR modulating drug.
Receiver operating characteristic (ROC) curves were generated to evaluate the predictive capacity of organoid FIS for clinical
responses. A Youden index was used to select the organoid cut-off point with the most optimal combination of sensitivity and
specificity from the ROC-curves (Youden, 1950). A leave-one-out cross validation further validated our findings (Leeflang et al.,
2008). As some patients were treated with two CFTR modifying treatments, we controlled for repeated measurments when calcu-
lating correlations and ROC-curves to evaluate a potential bias (Obuchowski, 1997; Lorenz, Datta and Harkema, 2011). Because
of the limited number of patients, no further subgroup analysis were performed. Statistical analysis were performed using GraphPad
Prism 7.02, IBM SPSS Statistics version 22 and R-studio version 0.99.441.e2 Cell Reports 26, 1701–1708.e1–e3, February 12, 2019
DATA AND SOFTWARE AVAILABILITY
All data is provided with the manuscript.
ADDITIONAL RESOURCES
The clinical trial registry numbers and Institutional Review Board (IRB) numbers of the two trials in which the patients with an S1251N
mutation were treated with genistein plus curcumin and ivacaftor are NTR4585/METC14-268/G-M and NTR4873/METC14-514/M
respectively. Additional information on these trials can be found on http://www.trialregister.nl/trialreg/index.asp. The IRB code of
the HUB-CF organoid biobank is 14-008.Cell Reports 26, 1701–1708.e1–e3, February 12, 2019 e3
